Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
Stocks · News reference
Reported Earlier, Guardant Health Said The FDA Approved Guardant360 CDx As A Companion Diagnostic To Identify HR-positive, HER2-negative Advanced Or Metastatic Breast Cancer Patients With ESR1 Mutations Who May Benefit From Astrazeneca’s ETCAMAH (Camizestrant)
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guardant Health shares are trading higher after the company announced the FDA approved Guardant360 CDx.
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) combined with CDK4/6 inhibitors for treating HR-positive, HER2-negative advanced breast cancer. The combination reduced disease progression or death risk by 56% compared to standard treatment. The FDA also approved Guardant360 CDx diagnostic test to identify patients with ESR1 mutations eligible for this therapy.